RxSight (RXST) Scheduled to Post Earnings on Monday

RxSight (NASDAQ:RXST) will announce its earnings results after the market closes on Monday, May 6th. Analysts expect the company to announce earnings of ($0.17) per share for the quarter. RxSight has set its FY 2024 guidance at EPS.Investors that wish to register for the company’s conference call can do so using this link.

RxSight (NASDAQ:RXST) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.10. The firm had revenue of $28.58 million for the quarter, compared to analysts’ expectations of $28.60 million. RxSight had a negative return on equity of 31.16% and a negative net margin of 54.57%. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

RxSight Price Performance

NASDAQ RXST opened at $61.68 on Friday. The business’s fifty day moving average price is $52.59 and its 200-day moving average price is $42.56. The stock has a market capitalization of $2.29 billion, a price-to-earnings ratio of -43.13 and a beta of 1.21. RxSight has a 1-year low of $18.09 and a 1-year high of $61.85.

Analyst Ratings Changes

Several equities analysts have recently weighed in on RXST shares. JPMorgan Chase & Co. increased their price target on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Stifel Nicolaus upped their price objective on RxSight from $54.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, February 29th. Oppenheimer upped their price objective on RxSight from $54.00 to $61.00 and gave the stock an “outperform” rating in a research note on Thursday, February 29th. Finally, Needham & Company LLC restated a “buy” rating and issued a $64.00 price objective on shares of RxSight in a research note on Thursday, April 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight currently has a consensus rating of “Buy” and an average price target of $49.63.

Insiders Place Their Bets

In other RxSight news, Director Bakker Juliet Tammenoms purchased 4,000 shares of the business’s stock in a transaction on Monday, February 12th. The stock was acquired at an average price of $50.38 per share, for a total transaction of $201,520.00. Following the purchase, the director now owns 25,840 shares of the company’s stock, valued at approximately $1,301,819.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other RxSight news, CFO Shelley B. Thunen sold 10,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $52.69, for a total value of $526,900.00. Following the completion of the sale, the chief financial officer now owns 13,938 shares in the company, valued at approximately $734,393.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Bakker Juliet Tammenoms purchased 4,000 shares of the business’s stock in a transaction on Monday, February 12th. The stock was acquired at an average price of $50.38 per share, with a total value of $201,520.00. Following the purchase, the director now directly owns 25,840 shares in the company, valued at approximately $1,301,819.20. The disclosure for this purchase can be found here. In the last quarter, insiders sold 59,490 shares of company stock worth $3,043,578. Corporate insiders own 21.13% of the company’s stock.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.